Aclaris Therap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M

Revenue: As of FY2026 Q1, the actual value is USD 1.996 M, beating the estimate of USD 1.322 M.

EPS: As of FY2026 Q1, the actual value is USD -0.15, beating the estimate of USD -0.1578.

EBIT: As of FY2026 Q1, the actual value is USD -23.71 M.

Net Loss

Aclaris Therapeutics, Inc. reported a net loss of - $19,824 thousand for the first quarter of 2026, which is an increase from the net loss of - $15,085 thousand for the first quarter of 2025.

Operational Metrics

• Loss from Operations: The loss from operations was - $22,192 thousand for the first quarter of 2026, an increase from - $18,084 thousand for the prior year period.
• Research and Development (R&D) Expenses: R&D expenses increased to $15,657 thousand for the first quarter of 2026 from $11,584 thousand for the prior year period, primarily due to expenses for ATI-052 clinical development and ATI-9494 manufacturing costs, partially offset by reduced ATI-2138 expenses.
• General and Administrative (G&A) Expenses: G&A expenses rose to $6,743 thousand for the first quarter of 2026 from $6,139 thousand for the prior year period, mainly due to increased professional, legal, and personnel expenses.
• Cost of Revenue: Cost of revenue was $395 thousand for the first quarter of 2026, down from $506 thousand for the first quarter of 2025.
• Licensing Costs: Licensing costs were $1,393 thousand for the first quarter of 2026, up from $1,010 thousand for the first quarter of 2025.
• Revaluation of Contingent Consideration: No revaluation of contingent consideration occurred in the first quarter of 2026, compared to $300 thousand in the first quarter of 2025.
• Total Costs and Expenses: Total costs and expenses were $24,188 thousand for the first quarter of 2026, an increase from $19,539 thousand for the first quarter of 2025.
• Total Other Income: Total other income decreased to $2,368 thousand for the first quarter of 2026 from $2,999 thousand for the first quarter of 2025.
• Stock-Based Compensation Expense: Stock-based compensation expense was $3,198 thousand for the first quarter of 2026, compared to $3,535 thousand for the first quarter of 2025.

Cash Flow

• Net Cash Used in Operating Activities: Net cash used in operating activities was - $18,149 thousand for the first quarter of 2026, an increase from - $13,057 thousand for the first quarter of 2025.

Liquidity and Capital Resources

• Cash, Cash Equivalents and Marketable Securities: As of March 31, 2026, Aclaris Therapeutics, Inc. held $190,788 thousand in cash, cash equivalents, and marketable securities, an increase from $151,363 thousand as of December 31, 2025.
• Proceeds from Stock Sale: In March 2026, the company sold 18.4 million shares of common stock, generating aggregate gross proceeds of $59.8 million.
• Total Assets: Total assets were $198,720 thousand as of March 31, 2026, up from $160,460 thousand as of December 31, 2025.
• Total Current Liabilities: Total current liabilities were $27,370 thousand as of March 31, 2026, a decrease from $28,645 thousand as of December 31, 2025.
• Total Liabilities: Total liabilities were $55,071 thousand as of March 31, 2026, down from $57,378 thousand as of December 31, 2025.
• Total Stockholders’ Equity: Total stockholders’ equity increased to $143,649 thousand as of March 31, 2026, from $103,082 thousand as of December 31, 2025.

Outlook / Guidance

Aclaris Therapeutics, Inc. expects its cash, cash equivalents, and marketable securities to fund operations through the end of 2028. The company anticipates reporting top-line results from its Phase 1b trials of ATI-052 in asthma and atopic dermatitis, and its Phase 2 trial of bosakitug, in the second half of 2026 and fourth quarter of 2026, respectively. Additionally, Aclaris Therapeutics, Inc. plans to initiate a Phase 2b program for ATI-052, a Phase 2b basket study for ATI-2138, and file an IND for ATI-9494, all in the second half or fourth quarter of 2026.